INTRODUCTION: Previous studies have found higher rates of adherence in @entity1 with @entity6 ( @entity6 ) using insulin pens compared to vial and syringe administration; however, little evidence is available to support this observation in elderly @entity1 . METHODS: This was a retrospective claims database analysis of a predominantly elderly Medicare Advantage with Prescription Drug (MAPD) insurance population consisting of 3172 insulin-na  ve @entity1 with @entity6 who initiated basal insulin using pre-filled pens or vial and syringe ('vial'). The index date was defined by the first pharmacy claim for basal insulin. Adherence, measured as proportion of days covered (PDC) and medication possession ratio (MPR), and persistence were evaluated in a 12-month follow-up period using an adjusted days' supply. Multivariate regression analyses and a Cox proportional hazards model were used to identify characteristics associated with adherence and non-persistence, respectively, and compare findings between the @entity8907 and vial groups. RESULTS: The @entity8907 cohort was slightly younger than the vial cohort (69.4 vs. 70.1  years, respectively; P  =  0.0338). Similar proportions of male @entity1 (53.3% vs. 56.8%; P  =  0.0529) occurred in both cohorts, and lower Deyo-Charlson Comorbidity Index (4.4 vs. 5.0; P  <  0.0001) was found for the @entity8907 cohort. Adjusted mean PDC was significantly higher in the @entity8907 cohort than the vial cohort (0.67 vs. 0.50; P  <  0.001), as was mean MPR (0.75 vs. 0.57; P  <  0.0001). Adjusted odds for adherence (PDC  >=   80%) showed a positive association with use of an insulin @entity8907 (odds ratio  =  2.19, 95%  CI: 1.86-2.59). The adjusted risk of non-persistence (discontinuation) was significantly lower (58%) in the @entity8907 cohort relative to the vial cohort (hazard ratio  =  0.42, 95%  CI: 0.38-0.45). Key limitations include assumptions related to accuracy and @entity1650 data, and specifically days' supply data used to measure insulin adherence. CONCLUSION: These findings suggest that @entity8907 devices improved insulin therapy adherence in a primarily elderly MAPD population with @entity6 . FUNDING: Novo Nordisk Pharmaceuticals, Inc.

Characteristics Relating to Adherence and Persistence to Basal Insulin Regimens Among Elderly Insulin-Na  ve XXXX with Type 2 @entity6 : Pre-Filled Pens versus Vials/Syringes.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1650 :: ('MESH:D001308', 'Disease') :: ['comprehensiveness of claims'] @entity6 :: ('MESH:D003920', 'Disease') :: ['T2DM', 'type 2 diabetes mellitus'] @entity8907 :: ('340348', 'Gene') :: ['pen']
@entity1 :: (9606,Species) :: ['Patients']
